ArticleClinical case reports2026
Cognitive Impairment in Sjögren's Disease: Unmasking Alzheimer's Through CSF Biomarkers. A Case Report.
Article in Clinical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cognitive Impairment in Sjögren's Disease: Unmasking Alzheimer's Through CSF Biomarkers. A Case Report.Clinical case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cognitive impairment in Sjögren's disease (SD) is typically attributed to autoimmune mechanisms or small vessel disease. However, its overlap with neurodegenerative pathology remains poorly understood. We report a 74-year-old woman with clinically diagnosed SD presenting with progressive memory decline. She demonstrated severe amnestic deficits on neuropsychological testing and had a cerebrospinal fluid (CSF) profile consistent with Alzheimer's disease (AD), including low Aβ1-42 and elevated total tau and phosphorylated tau. MRI revealed only mild small vessel disease. This case highlights the diagnostic importance of CSF biomarkers in distinguishing neurodegenerative from autoimmune cognitive syndromes. Though the overlap may be coincidental, it raises the question of whether systemic inflammation in SD could contribute to AD pathogenesis. This case illustrates how neurodegenerative disease may be overlooked in patients with autoimmune conditions. In individuals with SD and persistent amnestic symptoms, biomarker testing can help distinguish Alzheimer's pathology from autoimmune cognitive syndromes and guide more accurate diagnosis and care.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.